Cite

HARVARD Citation

    Wen, P. et al. (2018). Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-oncology. 20 (2), pp. 249-258. [Online]. 
  
Back to record